The value of the global gastrointestinal drug market will reach $48.4 billion within the next six years, says a report from GBI Research.
In the business intelligence provider’s report, a compound annual growth rate (CAGR) of 4.45% is predicted from the 2015 market value of $35.7 billion.
The report notes that the market has been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium (esomeprazole) from Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN), and Remicade (infliximab), which is sold by US healthcare giant Johnson & Johnson (NYSE: JNJ).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze